Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 27, 2019 - Issue 5
Submit an article Journal homepage
270
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Low-Dose Rituximab for Active Moderate to Severe Graves’ Orbitopathy Resistant to Conventional Treatment

Laurence Du Pasquier-FediaevskyDepartment of Internal Medicine, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris Cedex 12, FranceCorrespondence[email protected]
, MD,
Stefan AndreiDepartment of Internal Medicine, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris Cedex 12, France
, MD,
Michel BercheDepartment of Ophthalmology 4, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris Cedex 12, France
, MD,
Laurence LeenhardtInstitut E3M, Centre Hospitalier Universitaire Pitié-Salpétrière, Paris Cedex 13, France
, MD, PhD,
Emmanuel HéronDepartment of Internal Medicine, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris Cedex 12, France
, MD &
Sébastien RivièreDepartment of Internal Medicine, Centre Hospitalier Universitaire Saint-Antoine, Paris Cedex 12, France
, MD
Pages 844-850 | Received 06 Apr 2017, Accepted 12 Mar 2018, Published online: 13 Apr 2018

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jan Wolf, Kamila I. Mitka, Alicja Hubalewska-Dydejczyk, Irene Krämer & George J Kahaly. (2022) Drug safety in thyroid eye disease – a systematic review. Expert Opinion on Drug Safety 21:7, pages 881-912.
Read now

Articles from other publishers (11)

Naiara F. Xavier, Daniela Tavares Lucena & Antonio A. V. Cruz. (2023) Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?. Ophthalmic Plastic & Reconstructive Surgery 39:4, pages 307-315.
Crossref
Yu Hu, Jinhua Chen, Ken Lin & Xijie Yu. (2023) Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves’ophthalmopathy: a systematic review and meta-analysis. Frontiers in Endocrinology 14.
Crossref
Xuejiao Cui, Futao Wang & Cong Liu. (2023) A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy. Frontiers in Immunology 14.
Crossref
Yueyue Wang, Hao Hu, Lu Chen, Haitao Zhang, Tao Yang, Xiaoquan Xu & Huanhuan Chen. (2023) Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study. Frontiers in Endocrinology 13.
Crossref
Jing Chen, Gang Chen & Huilan Sun. (2021) Intravenous rituximab therapy for active Graves’ ophthalmopathy: a meta-analysis. Hormones 20:2, pages 279-286.
Crossref
Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Armando Patrizio, Stefania Camastra, Mario Miccoli, Gabriella Cavallini, Salvatore Benvenga & Alessandro Antonelli. (2021) Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy. Frontiers in Endocrinology 12.
Crossref
V.R. Cheredanova & Y.E. Poteshkin. (2021) Monoclonal antibodies in the treatment of thyroid eye disease. Vestnik oftal'mologii 137:4, pages 116.
Crossref
Alessandro Antonelli, Poupak Fallahi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Ilaria Ruffilli, Armando Patrizio, Debora Gonnella, Claudia Giusti, Camilla Virili, Marco Centanni, Yehuda Shoenfeld & Silvia Martina Ferrari. (2020) Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Practice & Research Clinical Endocrinology & Metabolism 34:1, pages 101388.
Crossref
Silvia Martina Ferrari, Poupak Fallahi, Giusy Elia, Francesca Ragusa, Stefania Camastra, Sabrina Rosaria Paparo, Claudia Giusti, Debora Gonnella, Ilaria Ruffilli, Yehuda Shoenfeld & Alessandro Antonelli. (2020) Novel therapies for thyroid autoimmune diseases: An update. Best Practice & Research Clinical Endocrinology & Metabolism 34:1, pages 101366.
Crossref
. (2019) Rituximab. Reactions Weekly 1772:1, pages 287-287.
Crossref
Elizabeth A. Insull, Zuzana Sipkova, Joel David, Helen E. Turner & Jonathan H. Norris. (2019) Early low‐dose rituximab for active thyroid eye disease: An effective and well‐tolerated treatment. Clinical Endocrinology.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.